For example, some studies have shown that the CCR5 Δ32 mutation is associated with older age at disease onset [16], delayed clinical progression of MS [17,18], and earlier mortality [19], whereas the CTLA-4 +49 A/G polymorphism affects disease course or progression in some populations [13,20,21,22]. This evidence concerns the gene CCR5 and myeloid sarcoma.